Adenosine and inflammation: What's new on the horizon?

Luca Antonioli, Balázs Csóka, Matteo Fornai, Rocchina Colucci, Endre Kókai, Corrado Blandizzi, G. Haskó

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Adenosine contributes to the maintenance of tissue integrity by modulating the immune system. Encouraging results have emerged with adenosine receptor ligands for the management of several inflammatory conditions in preclinical and clinical settings. However, therapeutic applications of these drugs are sometimes complicated by the occurrence of serious adverse effects. The scientific community is making intensive efforts to design novel adenosine receptor ligands endowed with greater selectivity or to develop innovative compounds acting as allosteric receptor modulators. In parallel, research is focusing on novel pharmacological entities (designated as adenosine-regulating agents) that can increase, in a site- and event-specific manner, adenosine concentrations at the inflammatory site, thereby minimizing the adverse systemic effects of adenosine.

Original languageEnglish
Pages (from-to)1051-1068
Number of pages18
JournalDrug Discovery Today
Volume19
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

Adenosine
Inflammation
Purinergic P1 Receptors
Ligands
Immune System
Maintenance
Pharmacology
Research
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Medicine(all)

Cite this

Antonioli, L., Csóka, B., Fornai, M., Colucci, R., Kókai, E., Blandizzi, C., & Haskó, G. (2014). Adenosine and inflammation: What's new on the horizon? Drug Discovery Today, 19(8), 1051-1068. https://doi.org/10.1016/j.drudis.2014.02.010

Adenosine and inflammation : What's new on the horizon? / Antonioli, Luca; Csóka, Balázs; Fornai, Matteo; Colucci, Rocchina; Kókai, Endre; Blandizzi, Corrado; Haskó, G.

In: Drug Discovery Today, Vol. 19, No. 8, 2014, p. 1051-1068.

Research output: Contribution to journalArticle

Antonioli, L, Csóka, B, Fornai, M, Colucci, R, Kókai, E, Blandizzi, C & Haskó, G 2014, 'Adenosine and inflammation: What's new on the horizon?', Drug Discovery Today, vol. 19, no. 8, pp. 1051-1068. https://doi.org/10.1016/j.drudis.2014.02.010
Antonioli L, Csóka B, Fornai M, Colucci R, Kókai E, Blandizzi C et al. Adenosine and inflammation: What's new on the horizon? Drug Discovery Today. 2014;19(8):1051-1068. https://doi.org/10.1016/j.drudis.2014.02.010
Antonioli, Luca ; Csóka, Balázs ; Fornai, Matteo ; Colucci, Rocchina ; Kókai, Endre ; Blandizzi, Corrado ; Haskó, G. / Adenosine and inflammation : What's new on the horizon?. In: Drug Discovery Today. 2014 ; Vol. 19, No. 8. pp. 1051-1068.
@article{8e4b8efa16e04baa909167db2befd0ec,
title = "Adenosine and inflammation: What's new on the horizon?",
abstract = "Adenosine contributes to the maintenance of tissue integrity by modulating the immune system. Encouraging results have emerged with adenosine receptor ligands for the management of several inflammatory conditions in preclinical and clinical settings. However, therapeutic applications of these drugs are sometimes complicated by the occurrence of serious adverse effects. The scientific community is making intensive efforts to design novel adenosine receptor ligands endowed with greater selectivity or to develop innovative compounds acting as allosteric receptor modulators. In parallel, research is focusing on novel pharmacological entities (designated as adenosine-regulating agents) that can increase, in a site- and event-specific manner, adenosine concentrations at the inflammatory site, thereby minimizing the adverse systemic effects of adenosine.",
author = "Luca Antonioli and Bal{\'a}zs Cs{\'o}ka and Matteo Fornai and Rocchina Colucci and Endre K{\'o}kai and Corrado Blandizzi and G. Hask{\'o}",
year = "2014",
doi = "10.1016/j.drudis.2014.02.010",
language = "English",
volume = "19",
pages = "1051--1068",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Adenosine and inflammation

T2 - What's new on the horizon?

AU - Antonioli, Luca

AU - Csóka, Balázs

AU - Fornai, Matteo

AU - Colucci, Rocchina

AU - Kókai, Endre

AU - Blandizzi, Corrado

AU - Haskó, G.

PY - 2014

Y1 - 2014

N2 - Adenosine contributes to the maintenance of tissue integrity by modulating the immune system. Encouraging results have emerged with adenosine receptor ligands for the management of several inflammatory conditions in preclinical and clinical settings. However, therapeutic applications of these drugs are sometimes complicated by the occurrence of serious adverse effects. The scientific community is making intensive efforts to design novel adenosine receptor ligands endowed with greater selectivity or to develop innovative compounds acting as allosteric receptor modulators. In parallel, research is focusing on novel pharmacological entities (designated as adenosine-regulating agents) that can increase, in a site- and event-specific manner, adenosine concentrations at the inflammatory site, thereby minimizing the adverse systemic effects of adenosine.

AB - Adenosine contributes to the maintenance of tissue integrity by modulating the immune system. Encouraging results have emerged with adenosine receptor ligands for the management of several inflammatory conditions in preclinical and clinical settings. However, therapeutic applications of these drugs are sometimes complicated by the occurrence of serious adverse effects. The scientific community is making intensive efforts to design novel adenosine receptor ligands endowed with greater selectivity or to develop innovative compounds acting as allosteric receptor modulators. In parallel, research is focusing on novel pharmacological entities (designated as adenosine-regulating agents) that can increase, in a site- and event-specific manner, adenosine concentrations at the inflammatory site, thereby minimizing the adverse systemic effects of adenosine.

UR - http://www.scopus.com/inward/record.url?scp=84906316272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906316272&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2014.02.010

DO - 10.1016/j.drudis.2014.02.010

M3 - Article

C2 - 24607729

AN - SCOPUS:84906316272

VL - 19

SP - 1051

EP - 1068

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 8

ER -